Abstract

ObjectivesTo develop and validate the imbalanced data correction based PET/CT radiomics model for predicting lymph node metastasis (LNM) in clinical stage T1 lung adenocarcinoma (LUAD).MethodsA total of 183 patients (148/35 non-metastasis/LNM) with pathologically confirmed LUAD were retrospectively included. The cohorts were divided into training vs. validation cohort in a ratio of 7:3. A total of 487 radiomics features were extracted from PET and CT components separately for radiomics model construction. Four clinical features and seven PET/CT radiological features were extracted for traditional model construction. To balance the distribution of majority (non-metastasis) class and minority (LNM) class, the imbalance-adjustment strategies using ten data re-sampling methods were adopted. Three multivariate models (denoted as Traditional, Radiomics, and Combined) were constructed using multivariable logistic regression analysis, where the combined model incorporated all of the significant clinical, radiological, and radiomics features. One hundred times repeated Monte Carlo cross-validation was used to assess the application order of feature selection and imbalance-adjustment strategies in the machine learning pipeline. Prediction performance of each model was evaluated using the area under the receiver operating characteristic curve (AUC) and Geometric mean score (G-mean).ResultsA total of 2 clinical parameters, 2 radiological features, 3 PET, and 5 CT radiomics features were significantly associated with LNM. The combined model with Edited Nearest Neighbors (ENN) re-sampling methods showed strong prediction performance than traditional model or radiomics model with the AUC of 0.94 (95%CI = 0.86–0.97) vs. 0.89 (95%CI = 0.79–0.93), 0.92 (95%CI = 0.85–0.97), and G-mean of 0.88 vs. 0.82, 0.80 in the training cohort, and the AUC of 0.75 (95%CI = 0.57–0.91) vs. 0.68 (95%CI = 0.36–0.83), 0.71 (95%CI = 0.48–0.83) and G-mean of 0.76 vs. 0.64, 0.51 in the validation cohort. The combination of performing feature selection before data re-sampling obtains a better result than the reverse combination (AUC 0.76 ± 0.06 vs. 0.70 ± 0.07, p<0.001).ConclusionsThe combined model (consisting of age, histological type, C/T ratio, MATV, and radiomics signature) integrated with ENN re-sampling methods had strong lymph node metastasis prediction performance for imbalance cohorts in clinical stage T1 LUAD. Radiomics signatures extracted from PET/CT images could provide complementary prediction information compared with traditional model.

Highlights

  • Lung cancer is the leading cause of cancer-related deaths in the world, with non-small cell lung cancer (NSCLC) making up 85% of lung cancer cases [1, 2]

  • A clinical trial demonstrated that compared with mediastinal lymph node sampling, extensive systematic lymph node dissection failed to improve the survival for patients with negative node [10]

  • After the feature selection process of Part 1, 368 and 272 radiomics features were included for PET and CT remaining features separately

Read more

Summary

Introduction

Lung cancer is the leading cause of cancer-related deaths in the world, with non-small cell lung cancer (NSCLC) making up 85% of lung cancer cases [1, 2]. Surgical lobectomy combined with systematic lymph node dissection remains the standard therapy for patients with stage T1 LUAD [5, 6]. There still has a controversy surrounding the idea of whether the systematic lymph node dissection is required for T1 stage LUAD [7, 8]. Using the systematic lymph node dissection in early-stage NSCLC without LNM was considered overtreatment [9]. A clinical trial demonstrated that compared with mediastinal lymph node sampling, extensive systematic lymph node dissection failed to improve the survival for patients with negative node [10]. Identifying patients with a higher risk of LNM from the stage T1 LUAD will assist surgeons to determine whether the systematic lymph node dissection should be performed or not

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.